Navigation Links
RSB Spine, LLC Announces First Implantation of the InterPlate(TM) L for the Lumbar Spine
Date:1/16/2008

CLEVELAND, Jan. 16 /PRNewswire/ -- RSB Spine, LLC, today announced the first implantation of its proprietary InterPlate(TM) L in the lumbar spine. The InterPlate L was approved as an interbody device in September 2007. The unique design offers a number of advantages over current devices. In addition, RSB Spine has recently completed the national rollout of its InterPlate C device for use in the cervical spine, which is being very well received by spine surgeons across the United States. The company also expects to introduce two new InterPlate products manufactured from a radiolucent polymer (PEEK, polyetheretherketone) later this year.

Fusion is one of the most common spinal procedures performed by neurosurgeons and orthopedic spine surgeons. The InterPlate C and InterPlate L are designed to facilitate rapid fusion and are used in conjunction with graft material to fuse spinal vertebrae.

Robert S. Bray, Jr., M.D., the inventor of the InterPlate and the first to use the lumbar version, said: "The InterPlate L simplifies the implant procedure and provides a very low profile implant with secure anti-backout protection of the screws for safety under the great vessels. It is a next generation from anterior lumbar plates, with the versatility for all levels."

RSB Spine Chief Executive Officer John A. Redmond said: "Today's announcement marks yet another milestone for our InterPlate family of products. Featuring a one-of-a-kind design and ease of insertion, the InterPlate L is expected to be highly attractive to many spine surgeons, as well as very competitive with other devices currently in the marketplace."

Redmond continued: "The InterPlate L has been exhibited at a number of spine meetings and the response has been gratifying, with many surgeons anxious to utilize this new device when released nationally."

RSB Spine is a privately held medical device company focused on developing innovative spinal implants. In 2004, RSB Spine sold its surgical instrument line to Jarit, an Integra LifeSciences Holding Corp. company and, in 2005, sold its cervical plate system to NuVasive, Inc.


'/>"/>
SOURCE RSB Spine, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):